Special Report - June 2008
This special edition of Envisage is intended to provide an in-depth assessment of the changing landscape of drug development and offer some insight into how medicines may be developed in the future.
- BIOspeak
-
Jim Greenwood, president and CEO of the Biotechnology Industry Organization (BIO) and a former member of the U.S. Congress, discusses the most critical policy challenges facing the industry today.
- Which Way Forward?
-
Amidst the constant need to secure steady financing, emerging biotech companies are considering options that will not only produce a larger return, but also increase the likelihood of getting a product to market.
- The New Face of Outsourcing
-
The pressing need to control costs and reduce development timelines has led many biopharmaceutical manufacturers to increasingly outsource components of their clinical research programs.
- Asian Migration
-
Access to patients, lower costs and increased efficiencies are leading to an explosion in the amount of clinical research being conducted in Asia.
- Joining Forces
-
Global partnerships enable big pharma to streamline drug development and refocus their efforts on core competencies.
Web Exclusives
- An Unbalanced Burden
-
A Q&A with Dr. Kathleen Squires, director of the infectious disease department at Jefferson Medical College in Philadelphia, illuminates the gender differences in the diagnosis and treatment of HIV.
- Turning the Corner
-
After decades of neglect, leading to a rapid increase in incidence, tuberculosis started gaining attention from industrialized nations over the past 10 years. With this new focus, TB’s incidence has started to decrease—but barely.